守护“记忆之魂”的中国痴呆临床研究引领者——贾建平教授

doi:10.3969/j.issn.1006-7795.2020.05.019

摘要/Abstract

摘要： 他为了实现"守护记忆、留住人间美好"的梦想，面对痴呆顽症，带领团队克服了难以言述的重重困难，终于找到了能提前5~7年预测记忆丧失的标志物，为早期预防提供了宝贵和长足的时间；他为了拿出中国人痴呆治疗方案，持之以恒地探索中国人群痴呆发生发展、流行的发病规律，首次报道了中国人口老化导致记忆障碍人数出现"井喷现象"（4 000多万），并提出控制危险因素可预防痴呆的观点；他一直潜心研究中国人痴呆的遗传规律和对携带有痴呆风险基因人群进行早期干预的可能性，首次报道了中国人13个致病基因新突变，提出了遗传干预策略；他为实现自主研发痴呆新药的载体工具，利用中国人特色基因构建了10种新的阿尔茨海默病动物模型，彰显了自力更生的研究精神；他为了规范中国的痴呆和认知障碍临床实践，主持制定《中国痴呆与认知障碍诊治指南》2010版和2015版，单篇发表相关论著23篇，极大地提高了我国临床诊治水平；为了推出痴呆新药，主持国内外临床试验20多项，证明中国新药丁苯酞和塞络通对血管性痴呆有明确疗效，报道于国际著名期刊，引起国内外同行关注；他和团队努力实践着构建防治痴呆的中国人方案，奠定了我国在痴呆领域研究的国际领先地位。他就是——贾建平教授。

关键词: 阿尔茨海默病, 痴呆, 生物标志物, 动物模型, 指南

Abstract: He has been devoting himself to the dream of "protecting memory and keeping the beauty of the world". He led the team to overcome the challenges to dementia and found a marker that can predict memory declines 5-7 years before the onset of symptoms, which provided precious chance of early prevention. In order to set up dementia treatment guidelines suitable for Chinese, he made great efforts to explore the occurrence and progress of dementia, epidemiology of dementia and the genetic rules of dementia in China. He has reported the "blowout phenomenon"(more than 40 million) in the number of memory disorders caused by ageing among Chinese population for the first time, and also pointed out that dementia could be prevented by controlling the risk factors. The focus of his research has been on the genetic pattern of dementia in Chinese and the possibility of early intervention in dementia patients carrying risk genes, and he reported pathogenic gene mutations in Chinese for the first time and proposed the genetic intervention strategies. To establish the animal models for development of anti-dementia drugs in China, he has constructed 10 new Alzheimer's disease animal models based on Chinese genetic variations, which highlighted the research spirit of self-reliance. To standardize the clinical practice of dementia and cognitive impairment in China, he was in charge of establishing the 2010 and 2015 editions of the "Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment in China", and published 23 articles, which greatly advanced the level of clinical diagnosis and treatment of dementia in China. In addition, he has led more than 20 clinical trials to develop the new anti-dementia drugs. He discovered two new drugs DL-3-n-butylphthalide and Sailuotong which showed a positive effect on vascular dementia. This achievement attracted attention of scholars in China and oversea. He and his group have immersed themselves in the exploration to prevent dementia in China and have taken a leading role in anti-dementia worldwide. The man is Professor Jia Jianping.

Key words: Alzheimer's disease, dementia, biomarker, animal models, guidelines

中图分类号:

R741.05

李妍. 守护“记忆之魂”的中国痴呆临床研究引领者——贾建平教授[J]. 首都医科大学学报, 2020, 41(5): 822-827.

Li Yan. A leader in clinical research on dementia in China who guards the “soul of memory”——Professor Jia Jianping[J]. Journal of Capital Medical University, 2020, 41(5): 822-827.

参考文献

[1] Jia J, Zhou A, Wei C, et al. The prevalence of mild cognitive impairment and its etiological subtypes in elderly Chinese[J]. Alzheimers Dement, 2014, 10(4):439-447.
[2] Jia J, Wang F, Wei C, et al. The prevalence of dementia in urban and rural areas of China[J]. Alzheimers Dement, 2014, 10(1):1-9.
[3] Jia J, Wei C, Chen S, et al. The cost of Alzheimer's disease in China and re-estimation of costs worldwide[J]. Alzheimers Dement, 2018, 14(4):483-491.
[4] Jia J, Zuo X, Jia X F, et al. Diagnosis and treatment of dementia in neurology outpatient departments of general hospitals in China[J]. Alzheimers Dement, 2016, 12(4):446-453.
[5] Jia L, Quan M, Fu Y, et al. Dementia in China:epidemiology, clinical management, and research advances[J]. Lancet Neurol, 2020, 19(1):81-92.
[6] Jia L, Du Y, Chu L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in China:a national cross-sectional study on 46011 adults ≥ 60 in 2015-2018[J]. Lancet Public Health, 2020.(Accepted)
[7] 贾建平. 中国痴呆与认知障碍诊治指南(2010年版)[M].北京:人民卫生出版社,2010.
[8] 贾建平. 中国痴呆与认知障碍诊治指南(2015年版)[M]. 北京:人民卫生出版社,2016.
[9] Jia J, Gauthier S, Pallotta S, et al. Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease[J]. Alzheimers Dement, 2017, 13(5):592-597.
[10] Jia J, Xu E, Shao Y, et al. One novel presenilin-1 gene mutation in a Chinese pedigree of familial Alzheimer's disease[J]. J Alzheimers Dis, 2005, 7(2):119-124; discussion 173-180.
[11] Jia L, Fu Y, Shen L, et al. PSEN1, PSEN2, and APP mutations in 404 Chinese pedigrees with familial Alzheimer's disease[J]. Alzheimer's Dement, 2020, 16(1):178-191.
[12] Jia L, Li F, Wei C, et al. Prediction of Alzheimer's disease using multi-variants from a Chinese genome-wide association study[J]. Brain, 2020.DOI:10.1093/brain/awaa364
[13] Jia L, Xu H, Chen S, et al. The APOE-ε4 exerts differential effects on familial and other subtypes of Alzheimer's disease[J]. Alzheimers Dement, 2020. DOI:10.1002/alz.12153.
[14] Jia L, Qiu Q, Zhang H, et al. Concordance between the assessment of Abeta42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid[J]. Alzheimers Dement, 2019, 15(8):1071-1080.
[15] Jia L, Zhu M, Kong C, et al. Blood neuro-exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage[J]. Alzheimers Dement, 2020.
[16] Jia J, Wei C, Liang J, et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease:a multicentre, randomized, double-blind, placebo-controlled trial[J]. Alzheimers Dement, 2016,12(2):89-99.
[17] Jia J, Wei C, Chen S, et al. Efficacy and safety of the compound Chinese medicine SaiLuoTong in vascular dementia:a randomized clinical trial[J]. Alzheimers Dement (N Y), 2018, 4:108-117.